Skip to main content
. 2022 Mar 2;22:28. doi: 10.1186/s12894-022-00978-w

Table 4.

Follow up details

Follow-up (mo) since sRARP, median (IQR) 22 (16–32)
Postoperative RT, n (%) 0
Metastasis, n (%) 0
Continence, n (%)
 Pad free after 3 months 14
 Pad free after 6 months 1
 Incontinent 0
Erections, n (%)
 Potent 5 (33%)
 Potent with PDE-5 inhibitor 4 (27%)
 Impotent 6 (40%)